In rotenone, 6-hydroxydopamine or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced rodent models of PD, EPO treatment restored the levels of tyrosine hydroxylase (TH) through the modulation of neuroinflammation [134,135,136]. Here, EPO is linked to Parkinson disease.